Kornimate/medical-research-clean huggingface dataset:
phenotype, genotype & biomarkers in als and related disorders

Conditions: Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Primary Lateral Sclerosis; Hereditary Spastic Paraplegia; Progressive Muscular Atrophy; Multisystem Proteinopathy

Summary: the goals of this study are: (1) to better understand the relationship between the phenotype and genotype of amyotrophic lateral sclerosis (als) and related diseases, including primary lateral sclerosis (pls), hereditary spastic paraplegia (hsp), progressive muscular atrophy (pma), and frontotemporal dementia (ftd); and (2) to develop biomarkers that might be useful in aiding therapy development for this group of disorders.

this study will recruit patients with als, als-ftd, pls, hsp, and pma, with a focus on incident cases. patients with both familial and sporadic forms of these diseases will be enrolled and followed longitudinally using a standardized set of evaluations. biological samples (blood, urine, csf) will be collected from all study participants, and will be used for biomarker discovery and validation. family members of affected individuals may also be enrolled and asked to contribute dna and biological samples to aid genetic and biomarker discovery.

Eligibility criteria:
inclusion criteria: * member of at least one of the following categories: 1. individuals with a clinical diagnosis of als or a related disorder, including ftd, hsp, pls, pma and msp (sporadic or familial). 2. family member of an enrolled affected individual. * able and willing to comply with relevant procedures. exclusion criteria: * affected with end or late stage disease. * a condition or situation which, in the pi's opinion, could confound the study finding or may interfere significantly with the individual's participation and compliance with the study protocol. this includes (but is not limited to) neurological, psychological and/or medical conditions.

Keywords: natural history, biomarkers, phenotype, genotype
vitrectomy and scleral shortening for macular hole retinal detachment or myopic traction maculopathy

Conditions: Macular Hole Retinal Detachment; Myopic Traction Maculopathy

Summary: the medical records of 16 eyes of 16 patients with macular hole retinal detachment or myopic traction maculopathy who received viterctomy including internal limiting membrane peeling and scleral shorting surgery were reviewed. best-corrected visual acuity, axial length, retinal reattachment and macular hole closure, the shape of staphyloma determined by optical coherence tomography and 3-dimensional magnetic resonance imaging were assessed.


Eligibility criteria:
inclusion criteria: * the inclusion criteria were patients who had highly myopic eyes with macular hole retinal detachment to myopic traction maculopathy exclusion criteria: * the patients with follow-up less than 6 months

Keywords: myopic traction maculopathy
fibrinogen and bleeding after cardiac surgery

Conditions: Complications; Bleeding; Coronary Artery Disease

Summary: the study hypothesis is that prophylactic fibrinogen infusion reduces postoperative bleeding and transfusion requirements after coronary artery bypass surgery (cabg) in patients with endogenous fibrinogen levels in the lower normal range. 60 patients will be included in a prospective, randomized double-blind placebo-controlled single center study.


Eligibility criteria:
inclusion criteria: * males and females * age 18 years and above * patients eligible for a first-time coronary artery bypass(cabg) surgery with a preoperative fibrinogen plasma concentration under 3,8 g/l * signed informed consent to participate in the study exclusion criteria: * patients undergoing redo surgery * clinical or laboratory signs of bleeding disorder * clinical or laboratory signs of significant liver disease, or,other significant disease or condition which in the investigators judgment interfere with hemostasis * any medications with agents which may interfere with hemostasis within 14 days prior to study start. clopidogrel and warfarin are withdrawn at least 24 hours before surgery. oral aspirin is allowed co-medication. * administration of other investigational drugs within eight weeks preceding the preentry examination * pregnant or lactating women

Keywords: fibrinogen postoperative bleeding transfusions cabg
dual acupoints stimulation alleviates pulmonary complication

Conditions: Pulmonary Complication; Postoperative Complications

Summary: stimulation at acupoints could be of beneficial effects during the perioperative period. in this study the investigators tend to verify the effect of dual acupoints stimulation on pulmonary complications after abdominal surgery in aged patients.

postoperative pulmonary complications contributes to the high morbidity of aged patients. the incidence could be as high as 30\~50% in those undergoing abdominal surgery. stimulation at acupoints have been to alleviate inflammatory response,improve pain management and decrease consumption of opioids, indicating a beneficial effect on pulmonary complications. in this study the investigators tend to verify the effect of dual acupoints stimulation on pulmonary complications after abdominal surgery in aged patients.

Eligibility criteria:
inclusion criteria: * informed consented * scheduled for elective abdominal surgery under general anesthesia * age \>=65 yrs exclusion criteria: * patients with contraindications to transcutaneous electrical stimulation * patients with difficulty in communication that may confuse follow-up * emergent surgeries * patients with pneumonia or needed ventilation before surgery * patients with history of pulmonary surgery * scheduled surgery involves thoracic manipulations * patients who attended clinical studies in the last 3 months

Keywords: acupoint stimulation elderly patients postoperative pulmonary complications
effects of pulmonary hypertension therapy in atypical pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: the purpose of this study is to characterize the clinical and hemodynamic response of pulmonary arterial hypertension (pah) therapy in patients with atypical pah and risk factors for left heart disease.

this is an observational prospective study to better understand the clinical impact of pulmonary arterial hypertension (pah) specific therapy in patients with atypical pah among those with risk factors for left heart disease the study involves detailed baseline clinical evaluation prior to initiation of pah therapy, followed by repeat clinical assessment after 6 months of medical therapy

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * pulmonary hypertension with mean pa pressure \>20 mmhg and a planned initiation of pulmonary arterial hypertension therapy * no active treatment for precapillary pulmonary hypertension * ambulatory (not wheelchair/scooter dependent) * presence of any risk factor for left heart disease will qualify for inclusion (either atrial fibrillation, body mass index\>30 kg/m2, arterial hypertension, diabetes, coronary artery disease or age\>60 years) exclusion criteria: * significant chronic obstructive pulmonary disease that is a primary contributor to symptoms in the opinion of the investigator * ischemia thought to contribute to dyspnea in the opinion of the investigator * obstructive hypertrophic cardiomyopathy * known infiltrative cardiomyopathy (amyloid) * constrictive pericarditis or tamponade * active myocarditis * complex congenital heart disease * more than mild aortic or mitral stenosis * intrinsic (prolapse, rheumatic) valve disease with more than moderate mitral, tricuspid or aortic regurgitation * acute or chronic severe liver disease as evidenced by any of the following: encephalopathy, variceal bleeding, inr \> 1.7 in the absence of anticoagulation treatment * terminal illness (other than hf) with expected survival of less than 1 year * enrollment or planned enrollment in another therapeutic clinical trial in next 3 months. * inability to comply with planned study procedures * pregnancy or breastfeeding mothers

Keywords: right heart catheterization
malmö breast tomosynthesis screening trial

Conditions: Breast Cancer

Summary: to compare digital breast tomosynthesis (dbt) with full field digital mammography (ffdm) regarding effectiveness as screening modalities.

mammography is the only approved method for breast cancer screening, but not all tumors can be detected with mammography. the main reason is overlapping structures that can either mimic or hide a tumor on a 2-dimensional image like mammography. digital breast tomosynthesis, (dbt) is a 3-dimensional x-ray technique that has been developed during the last years. a tomographic technique like dbt, which reduces or eliminates the detrimental effect of over- and underlying tissue, can probably help to find more tumors. this study aims to investigate whether more breast cancers can be detected with dbt compared to full field digital mammography (ffdm) in population invited to screening. an interim analysis will be performed during 2013 including the first 7,500 women of the study cohort.

Eligibility criteria:
inclusion criteria: * women 40-74 years old * in the regular population based mammographic screening program in malmö, sweden. exclusion criteria: pregnancy and women not speaking english or swedish -

Keywords: breast cancer screening sensitivity tomosynthesis
lung microbiota analysis in critically ill patients admitted to the intensive care unit.

Conditions: Lung Microbiota

Summary: our study aims to evaluate the relationship between the heterogeneity of pulmonary microbiota and clinical and outcome variables among critically ill patients admitted to the intensive care unit (icu). in patients undergoing invasive mechanical ventilation, an aliquot of bronchoalveolar lavage (bal) fluid will be used in the microbiology laboratory for the analysis of respiratory microbiota through next-generation sequencing technologies and validate computational techniques.

traditionally, microbiological investigations and clinical trials have contributed to the definition of lower airways as a physiologically sterile district, whose microbiological balance is altered when a respiratory infectious process occur. actually, the introduction of molecular study methods aiming at the identification of pathogens through genomic sequencing questioned the pardigm of "one bug-one disease", according to which we usually tend to consider a bronchial or pulmonary infectious event as due to the pathogenic role of a single exogenous microorganism. in such a contest, there are truly few data dealing with the characterization of respiratory microbiota in human bal as well as with the major determinants of this phenomenon and the possible impact on clinical and microbiological outcomes. our study, although it's a pilot one, aims to evaluate these aspects in a larger cohort of critically ill patients, observing the relationship between the heterogeneity of pulmonary microbiota and clinical and outcome variables. in patients undergoing invasive mechanical ventilation, an aliquot of bal fluid will be used in the microbiology laboratory for the analysis of respiratory microbiota through next-generation sequencing technologies and validate computational techniques. for each enrolled patient, we will register demographic, clinical and laboratory variables. the benefits deriving from this study lay in the possibility of improving the understanding of characteristics of critical patient's pulmonary microbioma and its clinical impact. such an information meets the increasingly topical need to customize medical interventions, especially in the context of critically ill patients.

Eligibility criteria:
inclusion criteria: * execution of bronchoalveolar lavage sampling, either for clinical indications or in the context of surveillance programs * acquisition of an informed consent exclusion criteria: * presence of significant coagulation abnormalities and/or severe respiratory failure * clearly bloody bal sample * small quantity of bal sample (\<5 ml)
plantar pressures after pressure release of the flexor digitorum brevis muscle versus a non-emission laser.

Conditions: Manual Therapy; Myofascial Pain Syndrome; Foot; Flat Foot

Summary: in this study we will test the effects of pressure release on the flexor digitorum brevis muscle on the plantar pressures variables using a pressure platform.


Eligibility criteria:
inclusion criteria: * participants who came to the clinic presenting with pain in both heels and who were diagnosed with active or latent myofascial trigger point in bilateral flexor digitorum brevis muscles. * myofascila trigger points of flexor digitorum brevis were the only ones diagnosed in the foot. * all participants with normal body mass, without obesity. exclusion criteria: * diagnosis of lower limb injury, such as plantar fasciitis, tendinopathy, bursitis, ligamentous injuries. * history of previous lower limb surgery. * participants will not be subjected to ankle stretching or any other treatment. * diabetes due to possible elevation of plantar pressure. * toe deformities such as hammertoes and hallux valgus due to possible alteration of plantar pressure.
misoprostol for reduction of blood loss during fibroid surgery

Conditions: Fibroids

Summary: the aim of this research work is to assess the impact of a single preoperative dose of buccal misoprostol in reducing blood loss during abdominal fibroid surgery.

this is a trial of women undergoing fibroid surgery at a university-affiliated tertiary care center. eligible participants will be randomized to receive preoperative 400ucg buccal (under the tongue) misoprostol or placebo on the basis of total fibroid volume, location, parity. intra-operative blood loss will be compared between groups.

Eligibility criteria:
inclusion criteria: * patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging (pelvic ultrasound or mri) within in last 12 months * age ≥ 18 years and ≤ 50 years * pre-operative hemoglobin \>8 g/dl * willing to have buccal administration of misoprostol or a placebo at least one hour pre-procedure. * ability to understand and the willingness to sign a written informed consent. * admissible medical/surgical history * can be previously treated with depo-lupron, depo-provera, or oral contraceptive pills * intraoperative use of vasopressin and uterine tourniquet is permissible * can have had prior cesarean delivery exclusion criteria: * patients who have had a prior abdominal myomectomy * post-menopausal women * patients with known bleeding/clotting disorders * patients with a history of gynecologic malignancy * history of allergic reactions attributed to compounds of similar chemical or biologic composition to misoprostol * any cases converted to abdominal hysterectomy or other additional elective surgical procedures performed at time of abdominal myomectomy will be excluded from data analysis * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Keywords: fibroids, leiomyomata, blood loss, misoprostol
relative bioavailability study of nadolol (1 x 80 mg) tablets under fasting conditions

Conditions: High Blood Pressure; Migraine Headaches; Chest Pain

Summary: the purpose of this study is to demonstrate the relative bioavailability of nadolol (1 x 80 mg) tablets under fasting conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.
microalbuminuria predicting ciaki after cag

Conditions: Contrast-induced Acute Kidney Injury; Microalbuminuria

Summary: the purpose of this study is to investigate the association between pre-existing microalbuminuria and contrast-induced acute kidney injury (ciaki) following coronary angiography (cag).


Eligibility criteria:
inclusion criteria: * patients with egfr≥30ml/min and without macroalbuminuria undergoing cag. exclusion criteria: * pregnancy * lactation * allergic history of contrast media * having been received contrast media within 7 days * use of nephrotoxic medications within 7 days * egfr \ 300 mg/g) * renal transplantation, emergent coronary angiography * cardiogenic shock, pulmonary edema * use of intra-aortic balloon pump (iabp) or mechanical ventilation * multiple myeloma and other malignant tumor * life expectancy less than 12 months

Keywords: coronary angiography contrast-induced acute kidney injury microalbuminuria
a registry study in lymphoma patients treated with liposomal doxorubicin

Conditions: Lymphoma

Summary: this study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. the treatment response and other adverse events will also be studied.


Eligibility criteria:
inclusion criteria: * histologically confirmed lymphoma * 18-80 years * ecog\<= 2 * newly diagnosed lymphoma * liposomal doxorubicin is planned in the treatment * normal lung function * no history or malignancy * informed consented exclusion criteria: * history of malignancy, now in the treatment * pregnant * serious infection * other uncontrollable conditions judged by the investigator
an evaluation of a public health campaign in a high school setting targeting pain related knowledge and beliefs

Conditions: Pain, Chronic

Summary: the beliefs held by students lead to behaviours in response to their pain which can be both helpful or a hindrance to how they manage their pain. the one-day education event aims to educate the cohort on the contemporary scientific understanding of persistent pain. it is hoped this event will result in an improvement in the alignment of beliefs and behaviours to contemporary understanding of persistent pain. the principal aim is to evaluate the pre-post beliefs about pain following a one-day pain education event.

the students will be asked to complete two questionnaires relating to their understanding of pain. one at the start of the conference and one at the end . the first questionnaire will gather demographic information (age, gender, ethnicity and any history of persistent pain). the following questions will be a series of multiple-choice questions relating to beliefs about persistent pain. the second questionnaire to be completed at the end of the day will be identical to the first, minus the demographic questions. each questionnaire should take 5-10 minutes to complete. so total involvement in this study will be less than 20 minutes. the questionnaires will be provided in an unmarked brown envelope. the envelope will contain two questionnaires one marked "before" and one marked "after". participants will be asked to complete the "before" questionnaire at the start of the day and then put it back in their envelope. at the end of the day, they will be asked to complete the "after questionnaire". participants will keep the envelope with them during the day and at no point will their name or any other identifiable information go on the form. at the end of the day, they will be asked to leave the anonymous envelope in a designated area in the room.

Eligibility criteria:
inclusion criteria: students at one of six schools in berkshire who had been offered the pain study day. aged above 16. providing consent to participate. exclusion criteria: students not providing consent.

Keywords: pain science education pain knowledge pain beliefs experience of education
real-world study of anti-tnfa treatment regimes of hyrimoz or zessly in patients with crohn´s disease

Conditions: Crohn´s Disease

Summary: hyrimoz™ was developed as a biosimilar to humiratm (inn: adalimumab) and zessly™ was developed as a biosimilar to remicadetm (inn: infliximab). within the biosimilar development program of hyrimoz™ and zessly™, two clinical confirmatory efficacy and safety studies were conducted: hyrimoz™ in plaque psoriasis and zessly™ in rheumatoid arthritis. both confirmatory phase iii studies demonstrated equivalent efficacy and similar safety and immunogenicity of hyrimoz™ to humiratm and zessly™ to remicadetm, respectively. the current study is designed to provide a systematic and consistent overview of the real-world data in biologic-naïve patients with moderate-to-severe crohn's disease (cd). the data collected in this observational trial will be used to increase the knowledge of the effectiveness of hyrimoz™ and zessly™ in clinical routine care in patients with moderate-to-severe cd.


Eligibility criteria:
the inclusion and exclusion criteria are to ensure the enrollment of patients receiving the drug according to the label of hyrimoz™ and the label of zessly™. patients observed in this study need to meet all of the following inclusion criteria and none of the exclusion criteria at enrollment: inclusion criteria 1. confirmed diagnosis of cd 2. harvey-bradshaw index (hbi) ≥ 5 3. treatment failure upon steroids / topical budesonide with or without immunosuppressants 4. males and females ≥ 18 years of age at enrollment 5. biologic-naive patients scheduled to receive hyrimoz™ or zessly™ and patients already receiving hyrimoz™ or zessly™ according to the label and at the discretion of the investigator for up to three months prior enrollment 6. provision of signed informed consent form exclusion criteria 1. patients with cd in clinical remission (hbi \< 5) 2. hemoglobin \< 8.5 g/dl 3. patients at imminent risk of scheduled intestinal surgery (stenosis, strictures, internal fistula) 4. any contraindications to hyrimoz™ or zessly™ according to the prescribing recommendations in each country 5. participation in an interventional clinical trial for immune-mediated inflammatory diseases (imids) or having received any investigational agent or procedure within 30 days prior to enrollment (consenting)

Keywords: crohn´s disease inflammatory bowel disease adalimumab infliximab biosimilar ibd-index
safety and efficacy of urs stents in the treatment of ureteral stricture

Conditions: Ureteral Stricture

Summary: a prospective observational study aimed to assess the efficacy and safety of allium ureteral stent long-term indwelling in the treatment of ureteral stricture.


Eligibility criteria:
inclusion criteria: 1. benign diseases: upj, ischemic injury caused by surgical separation, endoscopic surgery injury, heat injury by laser lithotripsy, infection (chronic inflammation, tuberculosis), peri-ureteral fibrosis caused by endometriosis, ureteral anastomotic stenosis after renal transplantation, ureteral fistula, multiple polyps; 2. malignant diseases: ureteral anastomotic stricture after urinary diversion, stricture caused by compression of abdominal and/or pelvic tumors, stricture caused by urinary tract tumors, stricture caused by radiotherapy for colon or cervical cancer, ureteral fistula exclusion criteria: 1. combine with hypertonic neurogenic bladder (except for patients with long-term indwelling catheter) 2. colon resection surgery patients -

Keywords: ureteral ureteral stent ureteral stricture